A Multicenter, Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors.
Latest Information Update: 26 Jun 2013
At a glance
- Drugs JI 101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 20 Apr 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
- 20 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2010 Planned end date changed from 1 Mar 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.